John Connolly speaks on an Endpoints News panel at the 2018 BIIS PharmCube/Endpoints conference in Shanghai (File photo)

John Con­nol­ly has a new mis­sion to tack on to his role at the Park­er In­sti­tute: in­ter­im chief of a buzzy biotech backed by a pair of bil­lion­aires

John Con­nol­ly, the new chief sci­en­tist at the Park­er In­sti­tute for Can­cer Im­munother­a­py, has a fresh mis­sion on his plate.

Con­nol­ly’s been tapped to take the in­ter­im CEO spot at 3T Bio­sciences, a buzzy Bay Area start­up that’s joined the whole cell ther­a­py 2.0 move­ment with the help of 2 tech bil­lion­aires who have shown a big in­ter­est in can­cer drug de­vel­op­ment: Pe­ter Thiel and Sean Park­er, who lent his name and di­rect in­volve­ment to his epony­mous non­prof­it.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.